Table 4.
B cell lymphoma antigens targeted by CAR-T cells
| CAR-T antigen | Clinical study | Disease |
|---|---|---|
| CD19 | Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma |
B-cell lymphoma; B-ALL |
| BAFF-R | Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions |
B- ALL; B-NHL |
| CD20 | Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma | R/R DLBCL |
| CD22 | CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL | R/R DLBCL |
| CD79b | Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas | B-cell lymphoma |
| CD37 | Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma | R/R B-NHL |
| PD-1 | CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma | PD-L1 Positive B-Cell Lymphoma |
| Igκ | T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells |
Low-grade NHL; B-CLL |
Abbreviations: CAR chimeric antigen receptor, B-ALL B-cell acute lymphoblastic leukemia, B-NHL B-cell non-Hodgkin lymphoma, R/R DLBCL relapsed and refractory diffuse large B cell lymphoma, PD-1 programmed cell death protein-1, PD-L1 programmed death ligand 1, B-CLL B-cell chronic lymphocytic leukemia